Loading stock data…
SRTA
$5.61-0.26 (-4.43%)
Market ClosedLast close Jun 9
Strata Critical Medical, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Strata Critical Medical, Inc. in the Healthcare sector is trading at $5.61. Wall Street consensus targets $9.25 (4 analysts), implying a +64.9% move over the next 12 months. The stock is currently 14% below its 52-week high of $6.50, remaining 14.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +64.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.61
Potential Downside
0%
Whystock Fair Value$5.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground tr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.45%
Volume
Today's trading volume
1.45M
Recent News
How The Story Is Shifting For Strata Critical Medical (SRTA) After New Analyst Assumptions
Strata Critical Medical is back in focus after an updated fair value estimate of $9.13, up from $8.81, reset expectations around what the stock might be worth on a modeled basis. That change comes alongside fresh Street commentary, where several firms have launched bullish coverage and one has lifted its price target by $0.25, tying their views to revised growth and profitability assumptions. As you read on, you will see how these shifting targets and narratives could shape how you follow...
Strata Critical Medical, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...
Joby Keeps Losing Money—and the Stock Keeps Rising
Joby Aviation reported better-than-expected first-quarter sales. Joby is still, essentially, presales. Joby stock gained 21% to $10.52 on Wednesday, while the and rose 1.5% and 1.2%, respectively.
Strata Critical Medical, Inc. Q1 2026 Earnings Call Summary
Moby summary of Strata Critical Medical, Inc.'s Q1 2026 earnings call
Strata (SRTA) Q1 2026 Earnings Call Transcript
Mathew Schneider: Thank you for standing by, and welcome to Strata's conference call and webcast for the quarter ended March 31, 2026. Before we get started, I would like to remind you of the company's forward-looking statement and safe harbor language. Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.